Status:
COMPLETED
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Non-Small-Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
30-40% of patients with lung cancer will develop bone metastases during the course of their disease, which can lead to pain, decreased mobility and skeletal complications. This study will investigate ...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed Non-small Cell Lung Cancer (NSCLC)
- Newly Diagnosed, Stage IIIA and Stage IIIB excluding patients with pleural effusion
- Patients must have received primary treatment for their disease and had no progression
Exclusion
- Diagnosed with NSCLC longer than 6 months ago
- Treatment with other bisphosphonates in past 12 months
- Presence of metastases
- Other protocol-defined inclusion and exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
437 Patients enrolled
Trial Details
Trial ID
NCT00172042
Start Date
March 1 2005
End Date
June 1 2010
Last Update
May 4 2015
Active Locations (69)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Jette, Belgium
2
Novartis Investigative Site
Leuven, Belgium
3
Novartis Investigative Site
Liège, Belgium
4
Novartis Investigative Site
Beijing, China